TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.1720
-0.0136 (-7.33%)
Nov 12, 2026, 2:53 PM EST - Market open
TScan Therapeutics Stock Forecast
TCRX's stock price has decreased by -82.97% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of $1.00, which predicts a 481.40% increase from the current stock price of 0.17.
Price Target: $1.00 (+481.40%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Sep 8, 2026.
Analyst Ratings
The average analyst rating for TScan Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $7 → $1 | Hold | Downgrades | $7 → $1 | +481.40% | Sep 8, 2026 |
| LifeSci Capital | LifeSci Capital | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Sep 2, 2026 |
| Needham | Needham | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Sep 2, 2026 |
| Wedbush | Wedbush | Hold Downgrades $5 → $1 | Hold | Downgrades | $5 → $1 | +481.40% | Sep 2, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 17, 2026 |
Financial Forecast
Revenue This Year
3.22M
from 10.33M
Decreased by -68.84%
Revenue Next Year
1.67M
from 3.22M
Decreased by -48.20%
EPS This Year
-0.79
from -1.00
EPS Next Year
-0.58
from -0.79
EPS and Forward PE are based on non-GAAP adjusted numbers.